Steadymed Ltd. CEO Jonathan Rigby told BioWorld that officials at his firm "feel more confident now than we ever have that we know exactly what the agency wants to see," after the FDA provided guidance regarding what's needed to resubmit the NDA for Trevyent.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
